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Abstract 
Fast dissolving oral films (FDFs) provide an alternative approach to increase consumer 
acceptance by advantage of rapid dissolution and administration without water. Usually FDFs 
require taste-masking agents. However, inclusion of these excipients could make developing 
the formulation a challenging task. Hence, this work employed fused-deposition modelling 
three-dimensional (FDM 3D) printing to produce single-layered (SLFDFs), or multilayered 
(MLFDFs) films, with taste-masking layers being separated from drug layer. Filaments were 
prepared containing polyethylene oxide (PEO) with ibuprofen or paracetamol as model drugs 
at 60C. Also filaments were produced containing polyvinyl alcohol (PVA) and paracetamol 
at 130C. Furthermore, a filament was prepared containing PEO and strawberry powder for 
taste-masking layer. FDFs were printed at temperatures of 165C (PEO) or 190ºC (PVA) with 
plain or mesh designs. HPLC and mass-spectroscopy analysis indicated active ingredient 
stability during film preparation process. SLFDFs had thicknesses as small as 197±21µm, and 
MLFDFs had thicknesses starting from 298±15µm. Depending on the formulation and design, 
mesh SLFDFs presented disintegration time as short as 42±7s, and this was 48±5s for mesh 
MLFDFs. SLFDFs showed drug content uniformity in the range of 106.0%-112.4%. In 
conclusion, this study provides proof-of-concept for the manufacturing of FDFs by using 3D 
printing. 
  
 
 
 
 
 
 
 
 
 
 
  
3 
 
1. Introduction  
Fast dissolving oral films (FDFs) provide the opportunity to administer medicines and avoid 
first-pass metabolism.1 FDFs may also be used in children2,3, patients with dysphagia4 and 
elderly patients.5  Although certain products such as paracetamol are available as oral 
suspension, these contain additives and sugar which may not be advisable for children.6 In 
addition, administrating oral liquid formulations to children is challenging by using syringes.7 
These concerns are triggers for development of more number of FDF formulations. 
FDFs are manufactured by hot melt extrusion or solvent casting methods, with the latter process 
being popular.8,9 The application of hot-melt extrusion process is growing due to its solvent-
free, continuous production, and less chance of drug instability as the result of not using 
solvents.8 In the formulation of FDFs rapid dissolution/release of the drug is required, and at 
the same time masking the drug taste is extremely important. Although there are handful of 
sweeteners and taste-masking agents, the presence of another ingredient in the mixture of 
formulation may significantly affect the physicochemical properties of the resulting paste/film. 
Consequently, further formulation adjustments/improvements are needed.9 Moreover, there are 
challenges in the development and manufacture of FDFs. These include: achieving desired 
FDF weight uniformity, chemical stability of active ingredient/excipients during 
manufacturing process, increasing film thickness due to the die swell phenomena, and the non-
homogenous flow of powder/paste in the extrusion chamber.8,10,11   
Three-dimensional (3D) printing has been employed in the development of complex oral 
dosage forms,12-19 and at commercial scale for the production of Spritam fast dissolving 
tablet.20,21 Hence, 3D printing may become an option to develop and manufacture desired FDFs 
by overcoming limitations of current FDF manufacturing techniques. In particular, 3D printing 
fused-deposition modelling (3D FDM) is closer to the hot-melt extrusion process. 3D FDM has 
been employed to develop various oral drug delivery systems.17,22-28  
Conventional FDM 3D printers utilise filaments to produce the desired objects. In this 
equipment, the filament passes through a narrow tubing system and rotating pulleys/gears in 
the 3D printer head. Here, the filament is heated and extruded through a nozzle with narrow 
diameter (typically 0.4 mm). FDM 3D printers can produce objects with reproducible 
dimensions, in particular when filaments are used with uniform diameters (low diameter 
tolerance).17 If there is an inconsistency in diameter of the filament (being too wide or too thin), 
either the printed object would have irregular dimensions and weight, or the extruder would 
fail to print. Hence, 3D FDM could potentially allow manufacturing FDFs with reproducible 
dimensions and physicochemical properties. In addition, 3D FDM provides the opportunity of 
laminating more than one-layer in a film. Then, these hypotheses have been examined in this 
paper. In the present work, 3D FDM was employed to produce 3D FDFs with taste-masking 
layers being printed on the drug-containing layer, and also to create mesh design of FDFs to 
reduce disintegration time. This property of 3D FDFS was compared to a commercially 
available FDF.  
2. Materials and Methods 
2.1. Materials 
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Paracetamol, polyvinyl alcohol (PVA, Mw 89,000-98,000, 99+% hydrolysed), polyethylene 
oxide (PEO) Mw 100,000 Da, PEO Mw 200,000 Da, poly (ethylene) glycol (PEG) Mw 4000 
Da, and PEG Mw 30,000 Da were purchased from Sigma Aldrich UK. Ibuprofen was supplied 
by BASF SE (Ludwigshafen, Germany). Starch was obtained from BDH Chemicals (Poole, 
England). Sodium starch glycolate was purchased from Shin-Etsu (Tokyo, Japan). 
Croscarmellose sodium was acquired from FMC Europe N.V. (Brussels, Belgium). Sodium 
lauryl sulphate (SLS) was supplied by Janssen Pharmaceuticals (Beerse, Belgium). Freeze 
dried strawberry powder was purchased from Healthy Suppliers (Hove, UK). Solvents were 
analytical grade. 
2.2. Preparation of Filaments 
The compositions of formulations are illustrated in Table 1. Drug and excipients were ground 
using pestle and mortar to form fine powder and then mixed together for 15 minutes utilising 
a turbula mixer (Type 2B, WAB, Muttenz, Switzerland). The contents were transferred to a 
single-screw Noztek Pro Filament Extruder (Noztek, Shoreham, UK) with the temperatures set 
at 60C for PEO and 130C for PVA. The nozzle die diameter was 1.6 mm. The extruder was 
placed at a height, which provided constant gravity pull on the extrudate to achieve straight 
filaments with uniform diameter. As the filament was extruded, the diameter was measured 
every 5-10 cm utilising a digital vernier caliper (RS Pro, Corby, UK) to ensure uniformity of 
the filament. The optimum diameter was between 1.60 – 1.80 mm. If the digital vernier caliper 
measurements indicated that the filament diameter became greater than this range, then an 
object with the weight of one gram was added to the first part of the extruded filament to 
increase the gravitational force on the extrudate. This was to maintain the desired diameter of 
the filament. The optimum diameter of the filament was crucial for using in the 3D printer 
(section 2.3). Preliminary studies showed that PEG with molecular weight of 30 kDa produced 
brittle filaments and only PEO 100 kDa and 200 kDa produced suitable filaments. Based on 
these observations, PVA with large molecular weight was considered. In addition, it was found 
that SLS improved drug release rate from films containing PEO. Starch and super 
disintegrating agents (i.e., sodium starch glycolate and croscarmellose) were added to the 
formulations to aid disintegration of films.  
2.3. 3D Printing of FDFs 
The films were printed using a fused-deposition modelling (FDM) Wanhao Duplicator 4 
Desktop 3D printer (Jinhua, Zhejiang, China), and SolidWorks 3DCAD (Dassault Systèmes 
SolidWorks Corp, Waltham, Massachusetts, USA) was used to design the film. The printer 
head included extruder nozzle with diameter of 0.4 mm. The shapes of films are provided in 
Table 1. The circular films were designed with the diameter of 20 mm and thickness of 0.2 
mm. The square films were designed with the length of 20 mm (the same width), and the height 
of 0.2 mm. Mesh films were printed as square shape, to reduce the complexity of designing 
films. MakerWare software (version 2.2.2.89, Brooklyn, NY, USA) was utilised to export the 
design into the printer. Printer extrusion parameters were: 40% infill for PEO films and 100% 
infill for PVA films, two shells, 0.10 mm layer height, extruder temperature 165ºC for PEO 
films and 190C for PVA films, extruder speed 70 mm/s for PEO films and 90 mm/s for PVA 
films, and with travelling speed of 60 mm/s for PEO films and 150 mm/s for PVA films. The 
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infill of 40% or 100% was chosen to achieve high density films with suitable mechanical 
strengths and adherence to the surface of 3D printer bed. Although hexagonal infill was the 
infill pattern, preliminary studies indicated that the infill pattern started to appear after printing 
first few layers on the printer bed. Sticky masking blue tape (3M) was utilised to facilitate 
the adhesion of printed films on the printer bed. The printer bed temperature was not altered 
(kept at room temperature). Printing time was two minutes for single-layer plain film, while 
the printing time was 30s for mesh film. The taste masking layer was designed in the 
MakerWare software at the same position of the drug containing layer but with 0.2 mm above 
the platform. Therefore, after printing the drug containing layer utilising one of the printer 
heads, the taste masking layer was printed on the drug containing layer using the other printer 
head. 
2.4. Differential Scanning Calorimetry (DSC) and Fourier Transform Spectroscopy (FTIR) 
DSC analysis (Perkin Elmer DSC 7 Waltham, Massachusetts, USA) was carried out on starting 
powders, filaments and films. Samples were accurately weighed and subsequently were 
enclosed in aluminium crimped crucibles. Initially samples were cooled to 0 °C at the rate of 
20°C/min, and held for 1 minute and then samples were heated from 0 to 90°C at 20°C/min for 
samples containing ibuprofen, from 0°C to 140°C at 20°C/min for samples containing 
paracetamol or PVA. In addition, the samples were cooled down again to 0°C and heated to 
220C at the rate of 20C/min for samples containing paracetamol or PVA. This was to 
simulate the heating procedure during 3D printing. FTIR was conducted on samples using a 
Perkin Elmer Spectrum BX II (Norwalk, CT, USA). 
2.5. Mass Spectroscopy (MS) 
Waters Micromass LCT mass spectrophotometer (Milford, Massachusetts, USA) was 
employed, which was also attached to Harvard apparatus pump 11. Nebulizer gas flow was 
used at 26 L/hr, desolvation gas flow at 789 L/hr, with desolvation temperature of 200ºC, 
capillary voltage at 3200 V, and extraction cone voltage at 3 V. Electrospray ionization was 
achieved by applying voltage of 35V. Desolvation was achieved by using nitrogen gas purging 
at 700 L/hr. Sample infusion flow rate was 20 µL/min. Samples for each formulation containing 
ibuprofen were prepared by dissolving 5 mg of powder, filament, or film with 5 ml of purified 
methanol, sonicated for 10 minutes; and the solution was filtered using 0.2µm Sartorius filters. 
Samples of powder, filament or film containing paracetamol with PVA were dissolved in 
water: methanol (50:50) solution. 
2.6. High Performance Liquid Chromatography (HPLC) 
An Agilent 1200 series HPLC (Stockport, Cheshire, UK) was used to analyse the drug content 
of the powders, filaments and films. To quantify ibuprofen, a C18 column was used with a 
mobile phase consisting of: 0.5 volumes of phosphoric acid, 340 volumes of acetonitrile and 
600 volumes of water then equilibrate and dilute to 1000 volumes with water. Weighed amount 
of ibuprofen standard and ibuprofen containing samples were dissolved in 2 mL of acetonitrile 
separately, and sonicated for 10 minutes. The resulting solution was diluted to 10 mL by using 
the mobile phase. The flow rate was set at 2 mL/min, and the detection spectrophotometer was 
set at 214 nm with injection volume of 20 µL.  
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Weighed amounts of the paracetamol standard and samples were transferred into volumetric 
flask containing mobile phase (3:1, methanol: water), sonicated for 2 minutes. Flow rate was 
set at 1.5 mL/min; detection spectrophotometer was set at 243 nm, and sample volume was 10 
µL. The stationary phase comprised of a C-18 column, ȝbondapak (300 mm×3.9 mm; 
Waters®, USA). The content uniformity was conducted only for formulation E (PVA films 
containing paracetamol). A calibration curve was prepared for paracetamol with a linear 
relationship between 0.017-1.56 mg/mL (R2 = 0.9976). Three films were analysed.  
2.7. Film Thickness 
The thickness of each film was determined by using a digital vernier caliper supplied by RS 
Pro (Corby, UK). Thickness of each film was measured from four directions. 
2.8. Tensile Properties 
Tensile testing was conducted using a TA-XT-Plus® texture analyser (Stable Microsystems 
Texture Analyser, London, UK). For the purpose of this test, longer films were printed. All the 
films tested had a uniform size of 100 mm×20 mm. This was to ensure that the instrument 
would be able to break the film (wider films were too strong for the machine). Each test strip 
was longitudinally placed in the tensile grips on the texture analyser, and the sequence of 
“Return to Start” was elicited. Initial grip separation was 40 mm and separation speed was set 
at 20 mm/s. The tensile strength was calculated from the following equation (1):  ܶ��ݏ��� ܵݐݎ���ݐℎ ሺ��ሻ = �௢௥�௘ �௧ ஻௥௘�௞ ሺ�ሻ஼௥௢௦௦ �௘�௧�௢௡�௟ ஺௥௘�௢௙ ��௠௣௟௘ ሺ௠2ሻ     (1) 
Values are expressed as mean ± standard deviation (n=3). 
2.9. Scanning Electron Microscopy 
3D printed films were sputter coated with gold using an Emitech K550 (Ashford, UK) coater 
and then visualized with a Philips XL20 (Eindhoven, Holland) scanning electron microscope 
(SEM). 
2.10. In vitro Dissolution Studies 
Dissolution studies (paddle method) were carried out on three (containing PVA) or six 
(containing PEO) films of each formulation using the United States Pharmacopeia dissolution 
apparatus II (Varian VK 7000, Agilent Technologies, CA, USA) at 50 rpm, in λ00 mL of 
phosphate buffer (pH 7.4 for ibuprofen and pH 5.8 for paracetamol). The release media were 
maintained at 37.3 ± 0.5°C. The amounts of active ingredients were measured using Cary 50 
UV-Vis spectrophotometer (Agilent Technologies, CA, USA) with wavelength of 243 nm for 
paracetamol and 265 nm for ibuprofen. For standard solutions, 100 mg of active ingredient was 
dissolved in 1000 mL volume of the buffer. The percentage of released drug and time for 
maximum drug release were recorded for each formulation. Results are presented as mean ± 
standard deviation. 
2.11. Disintegration Tests 
Disintegration time of each 3D film was determined in distilled water at 37 ± 0.5oC using 
Copley Scientific disintegration tester DTG 1000 (Copley Scientific, Nottingham, United 
Kingdom). Each film was placed in the tube over the 2 mm size mesh with disintegration disk 
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on it. The time was recorded for each film to disintegrate and pass the residue completely 
through the wire mesh. Three films were tested from each formulation.  
2.12. Powder X-ray Diffraction (PXRD) Analysis  
PXRD analysis was carried out on PVA pure powder, paracetamol pure powder, formulation 
G powder mixture, filaments and films of formulation G with the help of MiniFlex XRD 
(Riagaku, Japan). The PXRD analysis was carried out using the Cu K-alpha radiation (Ȝ = 1.54 
Å) at 15 mA and 30 kV. The samples were scanned between the 2 angle ranging from 5.0° to 
55° at the 0.01 step size (2) and scan step time of 2 seconds. RIGAKU data viewer software 
was used for data analysis. 
 
3. Results  
3.1. The morphology of FDFs 
Figure 1 presents photographic images of typical FDFs that were manufactured by 3D printing, 
and also corresponding SEM images. These show that films had two different surface 
morphologies. One side of the film had smooth surface, which was in contact with the printer 
bed. The other side had a porous structure. The presence of porous structure within the films 
may contribute to the rapid disintegration of the dosage form. Multilayered FDFs presented 
acceptable integrity of the taste-masking layers over drug containing layer (core layer). Also, 
it was needed to manufacture the strawberry filament with PEO at 70ºC to prevent charring of 
the flavouring agent. The films presented acceptable flexibility, and mesh FDFs were the most 
flexible samples with the ability to bend 90º with no obvious cracks on the films. This was 
considered as a typical deformation of the film, which may occur during packaging or handling. 
However, further deformations cracked the films.  
3.2. Weight and Thickness Uniformity of FDFs 
Table 2 presents the weight uniformity of FDFs, and thickness uniformity within a single film. 
It can be seen that the thickness variation was less than 4% within films, and weight uniformity 
was greater than 97%, apart from the formulation F, which was multilayered plain film. In this 
table, the results of Listerine®POCKETPAKS® breath strips are also presented. It can be seen 
that amongst 3D FDFs only mesh films had short disintegration time (42s ± 7s for single-
layered film and 48s ± 5s for double-layered film). However, these were higher than the 
disintegration time of the Listerine®POCKETPAKS® breath strips (14s ± 2s). PEO films 
became brittle during storage under ambient conditions. On the other hand, PVA films 
maintained their mechanical strengths under similar storage conditions. Furthermore, data in 
Table 2 indicates that polymers with lower molecular weight such as PEO 100k Da would 
achieve faster disintegration time compared to the same formulation but including polymers 
with larger molecular weight (such as PEO 200k Da). Table 2 also presents the dose contents 
of the films, and it can be seen that mesh films contained less drug compared to plain films, 
due to their particular designs. 
3.3. DSC Analysis of FDFs 
Figure 2A presents DSC thermograms of pure ibuprofen, PEO 100k Da, and PEO 200k Da 
powders. It can be seen that ibuprofen melted at 79.3C, and PEO 100k and PEO 200k melted 
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at 71.6C and 72.6C, respectively. Figure 2B illustrates the DSC thermograms of Formulation 
B for powder mixture, as filament and as film. It can be seen that the film or filament melted 
at lower temperatures (54.1C and 55.2C, respectively) compared to original powder forms. 
These suggest the dispersion of drug at molecular levels within the films or filaments. The 
formulation powder mixture melted at approximately 69C, which was lower than melting 
temperature of ibuprofen, PEO 100 kDa and PEO 200k Da. DSC data also suggested dispersion 
of paracetamol at the molecular levels within PVA filament or film. The melting peak of 
paracetamol was observed only in the DSC thermogram of powder mixture, not in filament or 
film (provided in supplementary information, Figure S3). The DSC thermograms are presented 
for paracetamol and PVA in supplementary information (Figures S1 and S2). 
3.4. Powder X-Ray Diffraction (PXRD) analysis 
The diffractogram of pure paracetamol powder presented a series of intense peaks, indicating 
of its crystalline nature (Figure 3A). On the other hand, the PXRD analysis of PVA showed 
only diffraction peaks at 20 and 40, suggesting some crystallinity (Figure 3A). The 
diffractogram of PVP-paracetamol mixture powder (formulation G) showed diffraction 
features for both of powders superimposed on the broad background (Figure 3B). However, 
the filament and the film patterns were characterised by diffraction peaks at 20 and 40, 
indicating presence of crystalline PVA aggregates (Figure 3B). This analysis further supported 
dispersion of paracetamol at molecular level within the filament and film. 
3.5. FTIR Analysis of FDFs 
FTIR results showed stability of the formulation ingredients during manufacturing of the films. 
Figure 4 presents typical examples of FTIR spectra for paracetamol with PVA (formulation 
G), as powder mixture, filament and film. Analysing the peaks shows presence of hydroxyl 
groups of PVA at wavenumbers of 3321 cm-1, in powder formulation and slight modifications 
(3294 cm-1) in the filament and film preparations. This could be due to the interactions of O-H 
groups of PVA with O-H group of paracetamol. This data also indicated the stability of 
paracetamol during manufacturing process of 3D FDFs. Similar trends were also observed for 
formulations containing ibuprofen (supplementary information, Figure S4). The FTIR spectra 
of pure paracetamol, PVA, PEO 100, PEO 200, and ibuprofen powders are provided in 
supplementary information (Figures S5-S9).  
3.6. Mass Spectroscopy and HPLC Analysis of FDFs 
In order to evaluate the stability of active ingredient in the manufacturing process, the mass-
spectra were obtained for formulation powder mixture, filament and film. Figure 5 presents 
mass-spectra of formulation C as powder mixture, filament and FDF. It can be seen that 
ibuprofen had a peak at m/z=229.0693 (ibuprofen + Na), and this can also be found in the 
spectra of filament and film. These outcomes indicated that the active ingredient remained 
chemically stable in the manufacturing process by the 3D printing method. Mass spectra of 
paracetamol in the filament and film also showed the stability of the active ingredient during 
preparation process of 3D FDF (supplementary information Figure S10). In addition, HPLC 
analysis confirmed the stability of ibuprofen and paracetamol in the manufacturing processes 
of filaments and films containing PEO (provided in supplementary information, Figures S11-
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S15). Furthermore, we carried out the HPLC analysis of the 3D FDFs containing PVA for 
determining the amounts of paracetamol, and to detect any drug degradation. It was observed 
that the films showed the paracetamol peak at the same retention time as the standard drug 
molecule (Figures S16 and S17). Thereby confirming that the paracetamol did not degrade in 
the printing process. In addition, drug contents in the films were evaluated for formulation E; 
and the values were found to be between 106.0% and 112.4% (109.6% ± 3.2%, mean ± standard 
deviation) of nominal drug content (15.6 mg per film).  
3.7. In vitro Dissolution Tests 
Figure 6 illustrates the in vitro release profiles of plain and mesh 3D FDFs (formulations C, E, 
F, G and H). The data shows that formulations C, G and H had faster drug release compared to 
formulations E and F. This data shows that drug release rate may be increased by optimising 
the design of the films (by manufacturing them as mesh). Also, it can be seen from Figure 6 
that adding taste-masking layers for plain films (formulation F) delayed the drug release 
significantly compared to core plain films (formulation E). However, this can be avoided by 
manufacturing films in a perforated shape (such as mesh). Films of formulations A, B, and D 
had similar drug release profiles (supplementary information, Figure S18).  
3.8. Tensile Strength 
The 3D films showed suitable mechanical strengths immediately after manufacturing. 
However, as mentioned previously, PEO films became brittle up on storage under ambient 
conditions. On the other hand, PVA 3D films maintained suitable mechanical strengths on 
storage under similar conditions. The tensile strength was 2.5 ± 0.03 MPa for 3D films of 
formulation E. While the tensile strengths were 0.57 ± 0.05 MPa and 1.27 ± 0.10 MPa, for 
single-layered mesh film (formulation G) and double-layered mesh film (formulation H), 
respectively. Figure 7 presents the texture profile analysis plots of the formulations G and H, 
and the saw-tooth curves were typical characteristics of mesh 3D films. Accordingly, plain 3D 
FDFs showed a single peak in the texture profile analysis plot (supplementary information, 
Figure S19). As expected, Figure 7 presents that films of formulation H (with taste-masking 
layer) were stronger than formulation G films (single-layered).  
4. Discussion  
This study showed proof-of-concept in preparing FDFs by 3D-printing. Depending on the 
design, 3D-films disintegrated on average between 42.2s and 150.0s. This range covers films 
manufactured by the hot melt extrusion method.11 However, 3D FDFs presented disintegration 
time longer than the disintegration time for a commercially available FDF 
(Listerine®POCKETPAKS® breath strips), or FDFs prepared by the solvent-casting method.11 
On the other hand, 3D FDFs showed both rapid and extended drug release profiles as seen 
previously for films prepared by solvent-casting or hot-extrusion methods.11,29 As expected, 
3D printing allowed layers of different compositions to be added on films. It should be noted 
that manufacture of layered oral films have been achieved previously by employing solvent 
casting method.30-32 However, the films manufactured by the 3D method (in particular mesh 
designs) had more thickness uniformity than layered films prepared by the solvent casting 
method. 32 
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In this study, we found that paracetamol was stable at extrusion temperature of 130C (for 
formulations containing PVA) and printing temperature of 190C (films containing PVA). 
Also, previous works have shown the stability of active ingredients during FDM 3D 
printing.25,26 However, in this work, the taste-masking agent charred at temperature of 130C. 
Therefore, separate filaments were prepared at a lower temperature that contained the taste-
masking agent; and this was printed on the drug containing layer to form multilayered FDFs. 
Nevertheless, the stability of the taste-masking agent should also be evaluated during the entire 
manufacturing process. Furthermore, additional studies will be required by employing 
volunteers or Electronic Tongue9 to evaluate the performance of the taste-masking layers. 
The drug release profiles of 3D FDFs depended on the design and presence of taste-masking 
layer. Plain FDFs with taste-masking layers showed significantly slower drug release rate 
compared to plain FDFS without the taste-masking layers. This could be due to the taste-
masking layer that acted as a barrier for drug molecules reaching the release media. 3D FDFs 
showed faster drug release compared to previously reported FDFs prepared by the hot extrusion 
method.11 This could be due to the presence of microcrystalline cellulose in the formulation to 
prevent the adherence of the paste to the extruder.11 On the other hand, plain 3D FDFs presented 
slower drug release compared to FDFs prepared by the solvent casting method. 4,11,29 This could 
be due to utilising polymers with large molecular weights for the 3D printing. However, this 
drawback was alleviated by printing the films in a mesh format. It should be added that printing 
FDFs in the mesh format resulted in the reduction of the drug content. Therefore, this may limit 
administrating large doses as mesh design of 3D FDFs. Furthermore, hot melt extrusion has 
been employed to develop PEO based buccal films.33 However, drug release was faster from 
3D films containing PEO compared to the buccal films.  The difference could be due to the 
different film thicknesses. The buccal films had 0.5 mm thicknesses,33 while 3D FDFs had 
smaller thicknesses.  
In this work the PEO based 3D films were printed at 40% infill, and PVA based 3D films at 
100% infill. However, PEO printed films appeared compact. As it is explained in section 2.3 
(3D Printing of FDFs), from preliminary studies we learned that first printed layers did not 
take into account either the infill percentage or infill pattern. Perhaps this was due to the 
formation of a wall of the printed object. Since printed films in this work were thin, therefore, 
two parameters (infill percentage and infill pattern) did not affect on the structure of the films. 
However, infill pattern and infill percentage are important parameters that could be investigated 
further to evaluate the effects of these parameters on the mechanical strengths and 
disintegration time of the films.  
It was observed that PEO 3D films became fragile during storage under ambient conditions, 
while 3D PVA films maintained their mechanical strength despite of PVA being a hydrophilic 
polymer. Oxidation of PEG by air in a wet environment has been shown before.34 In addition, 
a previous work investigated the effects of different storage conditions on the mechanical 
properties of PEO buccal films.33 This study found that the mechanical properties of PEO films 
changed significantly under 75% relative humidity (RH) storage conditions.33 As the RH was 
usually more than 75% in the ambient condition of where 3D FDFs were stored, then the results 
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of the previous study33 support fragmentation of PEO based 3D FDFs during storage under 
ambient conditions.  
PVA and PEO have been utilised successfully in the manufacture of drug delivery systems 
utilising 3D FDM. 17,26,28 In particular, PVA and PEO have been employed to manufacture 
disks by applying 3D FDM with infill of 100%.28 Furthermore, hydroxypropyl cellulose (HPC) 
and hydroxypropyl methyl cellulose (HPMC) have been employed to manufacture buccal films 
by applying the hot melt extrusion method,35,36 and disks by applying 3D FDM.28 Then, 3D 
printing may be employed to investigate these polymers for the manufacture of buccal films or 
fast dissolving oral films.  
Plasticisers are incorporated into the formulations of FDFs to achieve a suitable 
flexibility.11,29,37,38 PEG 400, glycerol and propylene glycol39 are amongst used plasticisers. 
PEG 40023 and glycerol28 also have been utilised in the manufacture of drug delivery systems 
utilising 3D FDM. However, in the manufacture of FDFs by FDM 3D printing, a certain 
mechanical strength (stiffness) of the filament was necessary in order to be used in the 3D 
printer. Therefore, in this study, plasticisers were not used, but 3D FDFs showed an acceptable 
flexibility suitable as an oral film.  
DSC thermograms of 3D FDFs suggested miscibility of the active ingredients with excipients 
in the formulation, which also have been observed in previous studies in preparing FDFs by 
solvent casting method.4,40 As a result, 3D FDFs met the weight uniformity that is required by 
pharmacopeia.41 This is apart from formulation F, which was 3-layered FDF. In addition, 3D 
FDFs showed the uniformity of content in the range of 106.0% to 112.4%, which was also in 
the range required by pharmacopeia (85%-115%).41 It should be noted that pharmacopeia 
requires ten samples to be tested. Therefore, 3D FDM could produce FDFs that meet the weight 
uniformity and the uniformity of contents required by pharmacopeia. 
5. Conclusions 
This paper shows proof-of-concept for 3D printing of fast dissolving oral films. 3D FDFs 
achieved weight uniformity and the uniformity of contents required by pharmacopeia. Also 3D 
printing allowed producing mesh design of FDFS to reduce the disintegration periods. 
Although the 3D FDFs were printed at high temperatures (165C or 190C), the drug molecules 
were stable. However the taste-masking agent was unstable. Therefore, it was deposited as a 
separate layer at a lower temperature on the drug-containing layer. Although FDFs can be 
produced either by hot-extrusion or solvent casting methods, 3D printing could reduce the 
development or production time.  
The manufacturing of strong filaments required utilising large molecular weight polymers, 
which delayed the disintegration time of plain 3D FDFs. Therefore, optimised FDM 3D printers 
that do not require utilising filaments may overcome this problem. 
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List of Figures 
Figure 1. Photographic images of films made from formulation H, formulation G, and 
formulation C (top row). Underneath of each photographic image, corresponding SEM 
photomicrograph is also presented. (SLFDF: single-layered fast dissolving oral film; MLFDF: 
multilayered fast dissolving oral film). 
Figure 2. A) DSC thermograms of ibuprofen, PEO 100k, and PEO 200k as pure powders. B) 
DSC thermograms of formulation B (containing PEO 200k) as powder mixture, filament and 
film. It can be seen that the DSC thermogram of ibuprofen disappears in the formulations as 
film or filament, indicating dispersion of ibuprofen molecules within PEO polymer.  
Figure 3. The powder X-ray diffraction patterns. A) Pure paracetamol powder (1) and pure 
PVA powder (2). B) Powder mixture of paracetamol and PVA (formulation G) (1), filament 
(2), and film (3). 
Figure 4. FTIR spectra of formulation G, as powder mixture, filament and film. These spectra 
suggest interactions between OH groups of PVA and paracetamol as filament or film, and the 
stability of the active ingredient during manufacturing of 3D FDFs.  
Figure 5. Mass-spectra of formulation C as film (top), filament (middle), and as powder 
mixture (bottom). These spectra illustrate the stability of ibuprofen during manufacturing 
process of FDF by 3D printing.  
Figure 6. The in vitro drug release profiles of 3D printed films (formulations C, E, F, G, H). 
Bars indicate standard deviations. 
Figure 7. Texture profile analysis plots of formulations G and H films, presenting higher 
tensile strength of formulation H film (mesh double-layered) compared to formulation G film 
(mesh single-layered). The saw-tooth profiles were due to the mesh designs of films. 
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Table 1: The weight percentage compositions of various ingredients in 3D printed FDF formulations.  
 
*Taste Masking Layer=PEO 100K (80%), freeze-dried strawberry powder (20%). 
PVA= Polyvinyl Alcohol 
SLS= Sodium lauryl sulphate 
PEO= Poly (Ethylene) Oxide  
 
 
 
Formulation PEO 
100K 
PEO 
200k 
PVA Starch Sodium 
Starch 
Glycolate 
Croscarmellose Ibuprofen Paracetamol SLS Texture Shape Number of 
layers 
A 58 - - 20 - - 20 - 2 Plain Circle 1 
B  - 58 - 20 - - 20 - 2 Plain Circle 1 
C - 40  18 - - 40 - 2 Plain Circle 1 
D  - 45 - - 10 2 - 42 1 Plain Circle 1 
E - - 80 - - - - 20 - Plain Circle 1 
F - - 63 - - 7 - 30 - Plain  Circle 3 (two taste 
masking 
layers*)  
G - - 73 - 7 - - 20 - Mesh Square 1 
H - - 73 - - 7 - 20 - Mesh Square 2 (one taste 
masking 
layer*) 
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Table 2: Physical characteristics and disintegration time of 3D-FDFs (n=3) 
 
Film Thickness ± 
SD (µm) 
Weight ± 
SD (mg) 
*Nominal 
Drug 
Content 
Mean± SD 
(mg) 
*Nominal 
Drug 
Content  
(%) 
Disintegration 
Time ± SD 
(s) 
A 242 ± 4 70.5 ± 0.7 13.9 ± 0.7 20 103 ± 9 
B 246 ± 8 67.4 ± 0.8 14.5 ± 0.5 20 120 ± 5 
C 235 ± 5 66.9 ± 0.7 24.8 ± 1.6 40 125 ± 11 
D 245 ± 5 52.6 ± 1.3 27.1 ± 1.2 42 122 ± 6 
E 374 ± 16 75.7 ± 2.2 15.1 ± 0.4 20 88 ± 21 
$F 885 ± 31 344.6 ± 58.7 24.5 ± 0.3 7 150 ± 25 
G 197 ± 21 42.6 ± 1.7 8.5 ± 0.3 20 42 ± 7 
**H 298± 15 81.1 ± 4.8 8.5 ± 0.3 11 48 ± 5 
Listerine® 
breath strips  
45 ± 6 33.6 ± 0.3 -  14 ± 2 
 
*The nominal content was calculated based on the weights of minimum 5 films for each 
formulation.  
$These films had three layers, one drug containing layer and two taste masking layers (no 
drug). The drug containing layer weighed 81.6 ± 0.9 mg. 
**These films had two layers, one drug containing layer and one taste masking layer (no 
drug). The drug containing layer weighed 42.6 ± 1.7 mg. 
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DSC data 
 
 
Figure S1. DSC thermogram of pure paracetamol powder (the black line is the reheat to 
simulate the heating process in the 3D printer). 
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Figure S2. DSC thermogram of pure PVA powder (the black line is the reheat to simulate the 
heating process in the 3D printer).  
 
 
Figure S3. DSC thermograms of physical mixture of Formulation G (blue line), extruded 
filament of Formulation G (green line), and printed film of Formulation G (red line). 
 
 
FTIR Data 
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Figure S4. FTIR spectrum of formulation B as filament. 
 
 
Figure S5. FTIR spectrum of pure paracetamol powder. 
 
 
 
Figure S6. FTIR spectrum of pure PVA powder. 
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Figure S7. FTIR spectrum of pure PEO 100 kDa powder. 
 
 
Figure S8. FTIR spectrum of pure PEO 200 kDa powder. 
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Figure S9. FTIR spectrum of pure ibuprofen powder. 
 
LC-MS data 
 
Figure S10. Mass spectra of paracetamol powder (pure active ingredient, bottom), and 
paracetamol in filament (middle) and film (top) for formulation E. 
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HPLC Data 
 
Figure S11. HPLC chromatogram of pure ibuprofen. 
 
 
Figure S12. HPLC chromatogram of ibuprofen in filament with PEO 200 kDa (formulation 
B). 
 
30 
 
 
Figure S13. HPLC chromatogram of ibuprofen film printed at 165 °C (formulation B). 
 
 
Figure S14. HPLC chromatogram of paracetamol powder. 
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Figure S15. HPLC chromatogram of paracetamol printed film containing PEO 200 kDa 
(formulation D). 
 
Figure S16. HPLC chromatogram of paracetamol standard powder, this was obtained 
separately while analysing formulation E films.  
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Figure S17. HPLC chromatogram of printed film containing paracetamol and PVA 
(formulation E). 
 
Release Profiles 
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Figure S18. The release profiles of ibuprofen and paracetamol from films of formulations A, 
B and D. Bars indicate standard deviations (n=6). 
 
Figure S19. Texture profile analysis plot of formulation E.  
 
 
 
